AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On March27, 2018, AveXis,Inc. (the “Company”) issued a press release announcing that Japan’s Ministry of Health, Labour and Welfare awarded the Company’s initial product candidate, AVXS-101, SAKIGAKE Designation for the treatment of spinal muscular atrophy Type 1. The full text of the Company’s press release regarding the announcement is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits


AveXis, Inc. Exhibit
EX-99.1 2 a18-9055_1ex99d1.htm EX-99.1 Exhibit 99.1     Media Inquiries: Lauren Barbiero W2O Group 646-564-2156 lbarbiero@w2ogroup.com   Investor Inquiries: Jim Goff AveXis,…
To view the full exhibit click here

About AVEXIS,INC. (NASDAQ:AVXS)

AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

An ad to help with our costs